These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Boswellic extracts and 11-keto-ß-boswellic acids prevent type 1 and type 2 diabetes mellitus by suppressing the expression of proinflammatory cytokines. Ammon HPT Phytomedicine; 2019 Oct; 63():153002. PubMed ID: 31301539 [TBL] [Abstract][Full Text] [Related]
8. Preventive effect of Ninjin-to (Ren-Shen-Tang), a Kampo (Japanese traditional) formulation, on spontaneous autoimmune diabetes in non-obese diabetic (NOD) mice. Kobayashi T; Song QH; Hong T; Kitamura H; Cyong JC Microbiol Immunol; 2000; 44(4):299-305. PubMed ID: 10832976 [TBL] [Abstract][Full Text] [Related]
9. The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling. Ohno T; Hasegawa C; Nakade S; Kitagawa J; Honda N; Ogawa M Biopharm Drug Dispos; 2010 Oct; 31(7):396-406. PubMed ID: 20623701 [TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor I (IGF-I) delays the onset of diabetes in non-obese diabetic (NOD) mice. Kaino Y; Hirai H; Ito T; Kida K Diabetes Res Clin Pract; 1996 Sep; 34(1):7-11. PubMed ID: 8968685 [TBL] [Abstract][Full Text] [Related]
11. The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice. Yang ZD; Chen M; Wu R; McDuffie M; Nadler JL Diabetologia; 2002 Sep; 45(9):1307-14. PubMed ID: 12242464 [TBL] [Abstract][Full Text] [Related]
12. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. Hancock WW; Polanski M; Zhang J; Blogg N; Weiner HL Am J Pathol; 1995 Nov; 147(5):1193-9. PubMed ID: 7485382 [TBL] [Abstract][Full Text] [Related]
13. Preventive effects of andrographolide on the development of diabetes in autoimmune diabetic NOD mice by inducing immune tolerance. Zhang C; Gui L; Xu Y; Wu T; Liu D Int Immunopharmacol; 2013 Aug; 16(4):451-6. PubMed ID: 23707775 [TBL] [Abstract][Full Text] [Related]
14. NO-mediated cytotoxicity contributes to multiple low-dose streptozotocin-induced diabetes but not to NOD diabetes. Yasuda H; Jin Z; Nakayama M; Yamada K; Kishi M; Okumachi Y; Arai T; Moriyama H; Yokono K; Nagata M Diabetes Res Clin Pract; 2009 Feb; 83(2):200-7. PubMed ID: 19117633 [TBL] [Abstract][Full Text] [Related]
15. In vivo effect of gangliosides on non-obese diabetic mice. Papaccio G; Chieffi Baccari G; Mezzogiorno V Acta Anat (Basel); 1993; 147(3):168-73. PubMed ID: 8213041 [TBL] [Abstract][Full Text] [Related]
16. Attempts to pharmacologically modulate prolactin levels and type 1 autoimmune diabetes in the non-obese diabetic (NOD) mouse. Durant S; Alves V; Coulaud J; El Hasnaoui A; Dardenne M; Homo-Delarche F J Autoimmun; 1995 Dec; 8(6):875-85. PubMed ID: 8824712 [TBL] [Abstract][Full Text] [Related]
17. Genistein and daidzein prevent diabetes onset by elevating insulin level and altering hepatic gluconeogenic and lipogenic enzyme activities in non-obese diabetic (NOD) mice. Choi MS; Jung UJ; Yeo J; Kim MJ; Lee MK Diabetes Metab Res Rev; 2008; 24(1):74-81. PubMed ID: 17932873 [TBL] [Abstract][Full Text] [Related]